SPARCL Study

Revision as of 23:01, 17 September 2013 by Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Objective== To study the effects of statins on incidence of recurrent stroke after a recent episode of stroke or...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

SPARCL Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of SPARCL Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on SPARCL Study

CDC on SPARCL Study

SPARCL Study in the news

Blogs on SPARCL Study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for SPARCL Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To study the effects of statins on incidence of recurrent stroke after a recent episode of stroke or transient ischemic attack

Methods

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) was a double blinded study with subjects who had at least one episode of stroke in the last one to six months and LDL levels of 100 to 190 mg/dl with no history of coronary artery disease. These patients were randomly assorted to receive either 80 mg of atorvastatin daily or placebo. The primary end point for the study was first fatal or non-fatal stroke.

Results

  • During the mean follow up period of 4.9 years, 11.2% of patients from the atorvastatin group and 13.1% of patients from the placebo experienced fatal/non-fatal stroke, with a 5 year absolute risk reduction of 2.2%.
  • The 5 year absolute risk reduction in major cardiovascular events was 3.5%.
  • The overall mortality rates were similar in both the groups.

Conclusion

Atorvastatin (80 mg daily) reduced the incidence of recurrent stroke and cardiovascular events in patients with a recent episode of stroke or transient ischemic attacks. However, the incidence of hemorrhagic stroke increased in the atorvastatin group.[1]

References

  1. Amarenco P, Bogousslavsky J, Callahan A; et al. (2006). "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 355 (6): 549–59. doi:10.1056/NEJMoa061894. PMID 16899775. Unknown parameter |month= ignored (help)